Innovative Clinical Trials: The LUNG‐MAP Study
CE Steuer, VA Papadimitrakopoulou, Roy S. Herbst et al. · Clinical Pharmacology & Therapeutics · 2015
Although the proportion of patients with squamous cell carcinoma of the lung has declined over the last two decades, the disease is still fatal for tens of thousands of patients each year. The treatment of non-small cell lung cancer has advanced rapidly over the past decade, providing novel, targeted therapeutic options to patients, but has mostly been limited to the adenocarcinoma histology. Efforts are currently underway to bring squamous cell carcinoma of the lung into this new era of targeted therapy. This article reviews the rationale and trial design for the "LUNG-MAP: S1400 Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer" study. This multi-institutional, multi-cooperative group trial aims to individualize treatment for patients with metastatic squamous cell carcinoma to one of five arms based on the genomic profile of the tumor. The goal of this clinical trial is to rapidly identify new active drugs and bring them as soon as possible through a registration process for patients with squamous cell lung cancer by utilizing a novel trial design and involving all key stakeholders in drug development in a national effort. This could serve as a paradigm for drug development for malignancies with wide molecular heterogeneity.
Cited by 69 works. doi:10.1002/cpt.88
Authors
- CE Steuer
- VA Papadimitrakopoulou
- Roy S. Herbst
- Mary Weber Redman
- FR Hirsch
- Philip C. Mack
- SS Ramalingam
- David R. Gandara
References
- Cancer statistics, 2013
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- Comprehensive genomic characterization of squamous cell lung cancers
- First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
- The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
- The BATTLE Trial: Personalizing Therapy for Lung Cancer
- Antitumor Activity of Pembrolizumab (Pembro; Mk-3475) and Correlation with Programmed Death Ligand 1 (Pd-L1) Expression in a Pooled Analysis of Patients (Pts) with Advanced Non–Small Cell Lung Carcinoma (Nsclc)
- Cyclin-Dependent Kinase Pathways As Targets for Cancer Treatment
- Functional Expression and Mutations of c-Met and Its Therapeutic Inhibition with SU11274 and Small Interfering RNA in Non–Small Cell Lung Cancer
- Signaling networks assembled by oncogenic EGFR and c-Met